期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 76, 期 -, 页码 125-131出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2014.02.020
关键词
Alzheimer's disease; Amyloid; Imaging agent; Homoisoflavonoid; Binding assay
资金
- Key Laboratory of Brain Function and Disease, Chinese Academy of Sciences [2012-2]
A series of homoisoflavonoids [(E)-3-benzylidenechroman-4-ones, 3a-I] as novel potential diagnostic imaging agents targeting beta-amyloid (A beta) plaques in Alzheimer's disease (AD) were synthesized and evaluated. In vitro binding studies using A beta(1-40) aggregates with [I-125]IMPY as the reference ligand showed that these compounds demonstrated high to low binding affinities at the K-i values ranged from 9.10 to 432.03 nM, depending on the substitution of the phenyl ring. Fluorescent staining in vitro indicated that one compound with a N,N-dimethylamino group intensely stained A beta plaques within brain sections of postmortem AD patients. Biodistribution studies in normal mice after i.v. injection of the radioiodinated homoisoflavonoid displayed good initial brain uptake (2.61% ID/g at 2 min post-injection) and rapid clearance from the brain (0.18% ID/g at 60 min), which is desirable for amyloid imaging agents. The results strongly suggest that these derivatives are worthy of further study and may be useful amyloid imaging agents for early detection of amyloid plaques in the brain of AD. (C) 2014 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据